Axel Bex
Impact in
- Pulmonary and Respiratory Medicine top 0.05%
- Renal cell carcinoma treatment
- Ferroptosis and cancer prognosis
- Cancer Research top 0.5%
- Cancer Genomics and Diagnostics
Papers in
-
- Renal cell carcinoma treatment 246
- Prostate Cancer Diagnosis and Treatment 13
- Prostate Cancer Treatment and Research 8
-
- Cancer Genomics and Diagnostics 43
- Co-authors
- Thomas Powles (53 shared papers)Lorenzo SO Marconi (41 shared papers)Börje Ljungberg (46 shared papers)Saeed Dabestani (39 shared papers)Karim Bensalah (24 shared papers)Thomas B. L. Lam (29 shared papers)Fabian Hofmann (25 shared papers)Alessandro Volpe (32 shared papers)
- Journals
- European Urology (62 papers)World Journal of Urology (23 papers)British Journal of Urology (22 papers)European Urology Oncology (20 papers)Annals of Oncology (16 papers)
- Partner nations
- NetherlandsUnited KingdomGermany
In The Last Decade
Axel Bex
347 papers receiving 18.1k citations
Axel Bex's Hit Papers
Peers
Comparison fields: 5 of 149
- Pulmonary and Respiratory Medicine 11.6k
- Cancer Research 2.7k
- Oncology 2.9k
- Molecular Biology 5.2k
- Surgery 2.7k
Countries citing papers authored by Axel Bex
This map shows the geographic impact of Axel Bex's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Axel Bex with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Axel Bex more than expected).
Fields of papers citing papers by Axel Bex
This network shows the impact of papers produced by Axel Bex. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Axel Bex. The network helps show where Axel Bex may publish in the future.
Co-authors
The 25 scholars most cited alongside Axel Bex, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
Showing the 20 most-cited of 366 papers — load more, or switch the sort, to bring in the rest.
| # | Work | ||
|---|---|---|---|
| 1 | EAU Guidelines on Renal Cell Carcinoma: 2014 Update Hit paper breakdown → | 2015 | 2278 |
| 2 | Epidemiology of Renal Cell Carcinoma Hit paper breakdown → | 2018 | 1133 |
| 3 | European Association of Urology Guidelines on Renal Cell Carcinoma: The 2019 Update Hit paper breakdown → | 2019 | 1113 |
| 4 | European Association of Urology Guidelines on Renal Cell Carcinoma: The 2022 Update Hit paper breakdown → | 2022 | 1008 |
| 5 | Renal cell carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up Hit paper breakdown → | 2019 | 869 |
| 6 | Systematic Review and Meta-analysis of Diagnostic Accuracy of Percutaneous Renal Tumour Biopsy Hit paper breakdown → | 2015 | 432 |
| 7 | Renal cell carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up Hit paper breakdown → | 2016 | 411 |
| 8 | Comparison of Immediate vs Deferred Cytoreductive Nephrectomy in Patients With Synchronous Metastatic Renal Cell Carcinoma Receiving Sunitinib Hit paper breakdown → | 2018 | 367 |
| 9 | European Association of Urology Guidelines Office Rapid Reaction Group: An Organisation-wide Collaborative Effort to Adapt the European Association of Urology Guidelines Recommendations to the Coronavirus Disease 2019 Era Hit paper breakdown → | 2020 | 251 |
| 10 | 2014 | 244 | |
| 11 | 2016 | 208 | |
| 12 | 2018 | 184 | |
| 13 | Renal cell carcinoma: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up Hit paper breakdown → | 2024 | 181 |
| 14 | 2019 | 178 | |
| 15 | 2015 | 172 | |
| 16 | 2007 | 171 | |
| 17 | Adjuvant atezolizumab versus placebo for patients with renal cell carcinoma at increased risk of recurrence following resection (IMmotion010): a multicentre, randomised, double-blind, phase 3 trial Hit paper breakdown → | 2022 | 168 |
| 18 | 2021 | 158 | |
| 19 | 2018 | 146 | |
| 20 | 2008 | 143 |
About Axel Bex
Axel Bex is a scholar working on Pulmonary and Respiratory Medicine, Cancer Research, Oncology, Surgery and Molecular Biology, having authored 366 papers that have together received 18.3k indexed citations. Recurring topics across this work include Renal cell carcinoma treatment (246 papers), Renal and related cancers (73 papers), Bladder and Urothelial Cancer Treatments (58 papers), Cancer Genomics and Diagnostics (43 papers), Cancer Immunotherapy and Biomarkers (29 papers), Prostate Cancer Diagnosis and Treatment (13 papers), COVID-19 and healthcare impacts (11 papers) and Prostate Cancer Treatment and Research (8 papers). The work is most often cited by research in Pulmonary and Respiratory Medicine (11.6k citations), Cancer Research (2.7k citations), Oncology (2.9k citations), Molecular Biology (5.2k citations) and Surgery (2.7k citations). Axel Bex has collaborated with scholars based in Netherlands, United Kingdom and Germany. Frequent co-authors include Thomas Powles, Lorenzo SO Marconi, Börje Ljungberg, Saeed Dabestani, Karim Bensalah, Thomas B. L. Lam, Fabian Hofmann, Alessandro Volpe, Milan Hora and Michael D. Staehler. Their work appears in journals such as European Urology, World Journal of Urology, British Journal of Urology, European Urology Oncology and Annals of Oncology.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.